Introduction#
Edwards Lifesciences, a leader in medical technology, has appointed Doretta Mistras as its new Chief Financial Officer (CFO), effective at the end of May. This transition comes as the company prepares for future growth and innovation in patient care.
Leadership Transition#
Doretta Mistras will take over from Scott Ullem, who has served as CFO since 2014. Ullem announced his departure from the role last October and will continue to assist the company as a strategic advisor during the transition period. Edwards’ CEO, Bernard Zovighian, expressed confidence in Mistras, stating that her extensive experience will be vital for the company’s strategic goals.
Doretta Mistras’ Background#
Before joining Edwards, Mistras was the CFO at Viatris, where she led the global finance team and managed financial planning and reporting. Her prior experience includes senior roles in healthcare investment banking at Citigroup and Goldman Sachs. Mistras holds degrees in international studies and economics from the University of Pennsylvania and the Wharton School, respectively.
Company Performance#
Edwards Lifesciences is known for its innovative approaches to structural heart care, boasting a market capitalization of $48 billion. The company has shown strong operational performance, with a 14% revenue growth over the past year and a gross profit margin of nearly 78%. Recently, the company reported first-quarter 2026 results, achieving $1.65 billion in revenue, which reflects a 12.7% year-over-year growth. This strong performance has led to positive reactions from analysts, with several maintaining or raising their price targets for the stock, currently trading near its 52-week high.